In pharmaceutical manufacturing, packaging failures during stability testing can result in compromised product quality, regulatory citations, or delayed approvals. These failures often stem from overlooked container-closure risks, inadequate validation, or environmental stress. This article presents real-world case studies where packaging systems failed during stability and offers practical lessons to help you prevent similar outcomes.
Case Study 1: Flip-Off Cap Discoloration and Detachment
Product: Parenteral injectable in Type I glass vial with aluminum crimp and flip-off cap
Issue: During 6-month accelerated stability (40°C/75% RH), flip-off caps were found discolored and loosely attached. Further, some caps detached during shipping.
Root Cause: Humidity and thermal stress degraded the internal coating of the aluminum cap, reducing adhesion.
Impact: Stability batch was rejected. Regulatory agency issued a 483 observation for lack of sealing validation under extreme conditions.
Resolution: Caps were upgraded to anodized aluminum with improved lacquer. Thermal cycling and torque validation were added to closure SOP.
Case Study 2: Blister Pack Delamination in Zone IVb
Product: Oral tablet in PVC/PVDC blister with aluminum foil
Issue: Visible delamination occurred in 3 out of 20 blister packs at 30°C/75% RH stability station. Tablets showed signs of moisture exposure.
Root Cause: Inadequate bonding strength between PVC and PVDC layers, aggravated by high humidity.
Impact: Moisture ingress led to tablet softening and color change. Data was not acceptable for submission.
Resolution: Foil specs were revised, and heat sealing parameters were re-validated. A new supplier with proven tropical zone performance was engaged.
Case Study 3: Glass Vial Cracking Post-Autoclave
Product: Aqueous injection in 10 mL Type I glass vial, terminally sterilized
Issue: 5% of vials showed micro-cracks after autoclaving and were flagged during visual inspection at the 3-month stability point.
Root Cause: Thermal expansion mismatch between vial and stopper during steam sterilization.
Impact: Risk of microbial contamination and sterility failure. Entire batch pulled from stability program.
Resolution: Stopper material was changed to a more thermally compatible butyl rubber. Pre-autoclave CCI testing added to QA protocol.
Case Study 4: Label Adhesion Failure Under Humidity
Product: Oral suspension in HDPE bottle with printed label
Issue: Printed labels peeled off at 25°C/60% RH and higher conditions during 12-month stability testing.
Root Cause: Incompatibility of adhesive with bottle surface and environmental conditions.
Impact: Loss of traceability and regulatory non-compliance. WHO audit flagged packaging inadequacy.
Resolution: Switched to wrap-around, pressure-sensitive labels with humidity-resistant adhesive. Packaging SOP was updated to include label adhesion stress testing.
Case Study 5: High Oxygen Ingress in PET Bottles
Product: Vitamin C syrup in PET bottle with screw cap
Issue: Assay of ascorbic acid dropped below 90% within 2 months at 30°C/65% RH stability condition.
Root Cause: PET material had insufficient oxygen barrier properties. Cap was not induction sealed.
Impact: Product failed shelf-life claims and stability protocol was voided.
Resolution: Upgraded to amber glass bottle. Added nitrogen flushing and induction sealing to minimize oxygen exposure.
Case Study 6: Torque Variation and Sealing Defect
Product: Multidose ophthalmic solution in plastic bottle with dropper tip and screw cap
Issue: Leakage observed in several units stored under accelerated stability. Microbial ingress was detected in 2 units.
Root Cause: Improper torque application during capping, causing seal inconsistency
Impact: Potential patient safety risk. Observed by EU inspector during product review.
Resolution: Installed torque monitoring sensors on capping equipment. Line clearance SOP revised to include torque audit at start and end of each shift.
Lessons Learned Across All Case Studies
- Validate packaging materials under all ICH stability conditions, not just long-term storage
- Conduct container closure integrity (CCI) testing pre- and post-storage simulation
- Use extractables and leachables data to proactively assess packaging interactions
- Perform label adhesion, torque, and seal testing as per worst-case transport and humidity exposures
- Include closure vendors in design qualification and documentation activities
- Document all findings in the packaging validation file for regulatory readiness
Regulatory Expectations and Inspection Readiness
According to WHO and ICH Q1A(R2), packaging systems must not alter the product quality, identity, strength, or purity. All changes in closure, label adhesive, or suppliers must be documented with impact assessments. GMP inspections increasingly focus on packaging performance during stability testing, with observations tied to insufficient CCI, torque validation, and component traceability.
How to Strengthen Packaging-Related SOPs
Use real-world cases to update your SOPs for:
- Closure inspection and storage
- Sealing process validation and torque checks
- Label print quality, adhesion, and readability tests
- Environmental simulation of packaging degradation
- CAPA and deviation management for packaging incidents
Refer to pharma SOP templates for examples covering packaging failures and preventive controls.
Conclusion
Packaging failures during stability testing can derail product approvals, compromise safety, and invite regulatory scrutiny. The case studies above demonstrate the wide range of issues that can arise—from humidity-induced label failure to oxygen ingress in plastic bottles. By implementing risk-based design, proactive testing, and robust documentation practices, pharmaceutical companies can avoid these costly errors and ensure compliance with global stability requirements.
References:
- ICH Q1A(R2): Stability Testing of New Drug Substances and Products
- USP : Container Closure Integrity Evaluation
- WHO TRS Guidelines on Packaging and Labeling
- FDA Guidance for Industry: Container Closure Systems
- EU GMP Annex 1 and Annex 15 on Packaging Validation